$ATEX

Guttman-McCabe Christopher sold $7.5M of ATEX

Guttman-McCabe Christopher (Chief Reg & Comm Officer) sold 91,437 shares of Anterix Inc. (ATEX) at an average of $82.46 ($81.32–$84.29, $7.54M total) across 4 trades on 2026-06-15.

Original reporting
SEC EDGAR · Guttman-McCabe Christopher
Published Jun 17, 2026, 11:11 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 17, 2026, 11:13 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ATEX
Bearish
medium confidence
Mentioned
$ATEX
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ATEXBearishLow
01

Why it matters

The newest disclosed fact is the officer’s open-market sale size (~$7.54M) and post-transaction holdings (77,807 shares).

02

Market read

Traders may note the insider selling signal, but it is unlikely to be a standalone driver of price without additional fundamental catalysts.

03

What to watch

Insider sales are more informative when paired with concurrent buying, guidance changes, or material operational/regulatory developments—none are present here.

Relevance 6/10Novelty 5/10Timing: Filed 2026-06-17; sale executed 2026-06-15.

Background

The article is an SEC Form 4 insider transaction disclosure for Anterix (ATEX).

Company-level read

Ticker impact

$ATEXBearishMedium confidence
Context

Anterix insider Form 4 shows officer Christopher Guttman-McCabe sold 91,437 shares in open-market trades for ~$7.54M.

Expected impact

Likely limited near-term impact; any reaction should be small unless accompanied by other news.

Evidence & confidence

The filing is a routine Form 4 open-market sale with no 10b5-1 plan stated; however, insider sales alone rarely drive sustained repricing without corroborating fundamentals.

Market effects

No clear sector read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

The sale could be for diversification, taxes, or pre-planned liquidity needs; absence of a stated 10b5-1 plan doesn’t prove bearish intent.

Key entities

  • Anterix Inc.

    Subject of the Form 4 insider sale disclosure.

  • Guttman-McCabe Christopher

    Chief Reg & Comm Officer who sold 91,437 shares across four trades.

Related articles

$ATEXMed

Anterix Inc. (ATEX): Results of Operations and Financial Condition

Anterix Inc. (ATEX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 atex-20260331xpressrelease.htm EX-99.1 Document Anterix Inc. Reports Full Fiscal Year 2026 Results Woodland Park, NJ – June 10, 2026 – Anterix (NASDAQ: ATEX) today announced fiscal 2026 fourth quarter and full fiscal year financial results for the year ended March 31, 2